Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Vyepti | eptinezumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lenvima and Keytruda | lenvatinib and pembrolizumab | advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rinvoq | upadacitinib | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Qinlock | ripretinib | Gastrointestinal stromal tumours | Reimburse with clinical criteria and/or conditions | Complete | ||
| Libtayo | cemiplimab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete | ||
| Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation, 6 years and older | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imbruvica | ibrutinib | Chronic lymphocytic leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Osphena | ospemifene | Dyspareunia, vaginal dryness | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 10, 2024